Dracen Pharmaceuticals Announces the Initiation of First-in-human Study of DRP-104 in Adult Patients With Advanced Solid Tumors!

Dracen Pharmaceuticals, Inc. has announced the start of a clinical trial of DRP-104, an anti-cancer substance developed by the team of Pavel Majer at IOCB Prague in collaboration with Johns Hopkins University in Baltimore (USA) @johnshopkinsu . The first patients have received the substance, and the initial phase of the trial will last approximately three years.

“The initiation of the phase one clinical trial of our substance is excellent news and an important milestone on the path towards a new treatment for oncology patients,” said Pavel Majer, Head of the drug discovery group at IOCB Prague.

Learn more on IOCB page or Dracen page!